Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655088 Administered by Intravenous Infusion in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel Group Design)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs BI 655088 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 19 Feb 2019 Status changed from active, no longer recruiting to completed.
- 12 Feb 2019 Planned End Date changed from 8 Feb 2019 to 15 Feb 2019.
- 12 Feb 2019 Planned primary completion date changed from 8 Feb 2019 to 15 Feb 2019.